# HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

> **NCT07748533** · PHASE1 · RECRUITING · sponsor: **Juventas Cell Therapy Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia (AIHA)

## Interventions

- **DRUG:** HY001N Cell Injection

## Key facts

- **NCT ID:** NCT07748533
- **Lead sponsor:** Juventas Cell Therapy Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-02
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748533, "HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07748533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*